54 / 69
54
REFERÊNCIAS
1.
Baccarani M, Dreyling M; ESMO Guidelines Working
Group. Chronic myelogenous leukemia: ESMO clinical
recommendations for diagnosis, treatment and follow-up.
Ann Oncol 2009;20 Suppl 4:105-7.
2.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz
MJ, Porwit A, et al. The 2008 revision of the World Health
Organization (WHO) classification of myeloid neoplasms
and acute leukemia: rationale and important changes.
Blood 2009;114:937-51.
3.
Tefferi A, Vardiman JW. Classification and diagnosis of
myeloproliferative neoplasms: the 2008 World Health
Organization criteria and point-of-care diagnostic
algorithms. Leukemia 2008;22:14-22.
4.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G,
Verstovsek S, et al. Chronic myeloid leukemia (CML)
with P190 BCR-ABL: analysis of characteristics, outcomes,
and prognostic significance. Blood 2009;114:2232-5.
5.
Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K,
Watmough SJ, et al. Chronic myeloid leukemia patients
with the e13a2 BCR-ABL fusion transcript have inferior
responses to imatinib compared to patients with the e14a2
transcript. Haematologica 2009;94:1362-7.
6.
de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ,
Beltrão AC, Bentes IR, et al. Differential molecular
response of the transcripts B2A2 and B3A2 to imatinib
mesylate in chronic myeloid leukemia. Genet Mol Res
2005;4:803-11.
7.
Sharma P, Kumar L, Mohanty S, Kochupillai V. Response
to Imatinib mesylate in chronic myeloid leukemia patients
with variant BCR-ABL fusion transcripts. Ann Hematol
2010;89:241-7.